Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_assertion type Assertion NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_head.
- NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_assertion description "[Diazoxide is the first-line drug for the rare forms of CHI for long-term treatment but is not entirely effective in some of these rarer defects (GCK, MCT1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_provenance.
- NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_assertion evidence source_evidence_literature NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_provenance.
- NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_assertion SIO_000772 21186003 NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_provenance.
- NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_assertion wasDerivedFrom befree-20140225 NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_provenance.
- NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_assertion wasGeneratedBy ECO_0000203 NP364621.RA1d2MNmHeqh3hmBEFxmsoZhyBWtNIcbpTzm5dKTZqNgY130_provenance.